Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 3/20 | 0.58 |
| ▸ | PDK2 | Q15119 | 3/20 | 0.58 |
| ▸ | PDK3 | Q15120 | 3/20 | 0.58 |
| ▸ | PDK4 | Q16654 | 3/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | DHODH | Q02127 | 1/20 | 0.42 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30447460 | 1.00 | PDK1 (0.58) | PDK1PDK2PDK3PDK4HTT | |
| SCHEMBL12666582 | 0.88 | PDK1 (0.67) | PDK1PDK2PDK3PDK4HTT | |
| SCHEMBL12666585 | 0.88 | L3MBTL1 (0.52) | PDK1PDK2PDK3PDK4HTT | |
| SCHEMBL15569990 | 0.85 | PDK1 (0.55) | PDK1PDK2PDK3PDK4GAA | |
| SCHEMBL20362848 | 0.81 | PDK1 (0.50) | PDK1PDK2PDK3PDK4HTT | |
| SCHEMBL3793230 | 0.81 | PDK1 (0.55) | PDK1PDK2PDK3PDK4HTT | |
| SCHEMBL14866056 | 0.81 | PDK1 (0.70) | PDK1PDK2PDK3PDK4HTT | |
| SCHEMBL5022147 | 0.81 | GAA (0.50) | PDK1PDK2PDK3PDK4GAA | |
| SCHEMBL29656890 | 0.80 | ALDH1A1 (0.44) | PDK1PDK2PDK3PDK4HTT | |
| SCHEMBL2971730 | 0.80 | ALDH1A1 (0.44) | PDK1PDK2PDK3PDK4HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250122174-A1 | Heteroaryl Compounds As HPK1 Inhibitors And Methods Of Using Same | SHENZHEN YUANLI SHENWAN INNOVATIVE MEDICINE CO LTD (CN) | 2025-04-17 | — | — | US | disclosed |
| WO-2023137406-A1 | HETEROARYL COMPOUNDS AS HPK1 INHIBITORS AND METHODS OF USING SAME | SHENZHEN IONOVA LIFE SCIENCE CO., LTD. (CN) | 2023-07-20 | — | — | WO | disclosed |
| WO-2023137406-A1 | HETEROARYL COMPOUNDS AS HPK1 INHIBITORS AND METHODS OF USING SAME | SHENZHEN IONOVA LIFE SCIENCE CO., LTD. (CN) | 2023-07-20 | — | — | WO | disclosed |
| US-10017478-B2 | Inhibitors of ACK1/TNK2 tyrosine kinase | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-10017478-B2 | Inhibitors of ACK1/TNK2 tyrosine kinase | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-20180155297-A1 | INHIBITORS OF ACK1/TNK2 TYROSINE KINASE | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2018-06-07 | — | — | US | disclosed |
| US-20180155297-A1 | INHIBITORS OF ACK1/TNK2 TYROSINE KINASE | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2018-06-07 | — | — | US | disclosed |
| US-9850216-B2 | Inhibitors of ACK1/TNK2 tyrosine kinase | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-9850216-B2 | Inhibitors of ACK1/TNK2 tyrosine kinase | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-20160176826-A1 | INHIBITORS OF ACK1/TNK2 TYROSINE KINASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160176826-A1 | INHIBITORS OF ACK1/TNK2 TYROSINE KINASE | TNK1, TNNI3K, TNK2 | PDK1 441/4885PDK2 140/4885PDK3 220/4885 |
| US-10017478-B2 | Inhibitors of ACK1/TNK2 tyrosine kinase | TNK1, TNNI3K, TNK2 | PDK1 441/4885PDK2 140/4885PDK3 220/4885 |
| US-20180155297-A1 | INHIBITORS OF ACK1/TNK2 TYROSINE KINASE | TNK1, TNNI3K, TNK2 | PDK1 441/4885PDK2 140/4885PDK3 220/4885 |
| US-20250122174-A1 | Heteroaryl Compounds As HPK1 Inhibitors And Methods Of Using Same | SGK1, HYPK, PCK1 | PDK1 229/4885PDK2 89/4885PDK3 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.